Skip to main content
Orexo logo

Orexo — Investor Relations & Filings

Ticker · ORX ISIN · SE0000736415 LEI · 549300LJ5CCWDPTK9Z08 ST Manufacturing
Open in API
Filings indexed 843 across all filing types
Latest filing 2010-02-25 Legal Proceedings Report
Country SE Sweden
Listing ST ORX

About Orexo

https://orexo.com/

Orexo is a commercial-stage pharmaceutical company focused on developing improved pharmaceuticals and digital therapies. The company addresses unmet patient needs, particularly within substance use disorders and mental health. It leverages proprietary drug delivery and formulation technologies to create innovative treatment solutions. Orexo's activities span research, development, and commercialization of its products.

Recent filings

Filing Released Lang Actions
Legal Proceedings Report 2010
Legal Proceedings Report Classification · 1% confidence The document is a press release dated February 25, 2010, announcing that the partner Kyowa Hakko Kirin has submitted a New Drug Application (NDA) in Japan for the drug KW-2246 (Abstral). This announcement concerns a specific corporate event related to regulatory submission and partnership activity, rather than a full financial report (like 10-K or IR) or a general shareholder vote result. Since it is an announcement about a regulatory filing/submission (NDA), and it is not a general regulatory filing fallback (RNS) or a specific M&A/Financing event, it best fits the category for general corporate news that doesn't fit elsewhere, or potentially a specific regulatory/legal update. Given the context of drug development and regulatory submission, it is a significant corporate event announcement. However, none of the categories perfectly capture 'Regulatory Submission Announcement' for a drug. It is not a Director's Dealing (DIRS), Dividend (DIV), or Earnings Release (ER). It is a specific announcement about a legal/regulatory step in drug development. The closest fit among the provided options for a specific, non-financial, non-management change announcement that is not a standard financial report is often the general Regulatory Filings (RNS) or potentially Legal Proceedings Report (LTR) if the NDA submission is viewed as a formal regulatory action. Given that it is a positive announcement about a submission, and not a negative legal proceeding, RNS (General regulatory announcements and fallback) is the most appropriate general category for this type of specific corporate update that doesn't fit the core financial/governance/management categories. Alternatively, since it is a formal submission to a regulatory body (NDA), it could be argued as a type of regulatory filing, but RNS is the designated fallback for miscellaneous regulatory announcements. I will classify it as RNS as it is a specific regulatory update announcement that doesn't match the other specific codes.
2010-02-25 Swedish
Earnings Release 2009
Earnings Release Classification · 1% confidence The document is titled "Orexo AB (publ.) – bokslutskommuniké januari-december 2009" and contains key financial highlights for the full year (januari-december 2009) and the fourth quarter, including net sales, net result, and earnings per share, along with a CEO's comment and updates on product pipelines and licensing deals. The term "bokslutskommuniké" translates to 'year-end report communication' or 'preliminary annual financial report'. Since it provides a comprehensive summary of the full year's financial performance and operational highlights, it aligns best with the definition of an Annual Report (10-K) or, given the context of a Swedish company potentially filing preliminary results before the full 10-K equivalent, an Interim/Quarterly Report (IR) if it were only quarterly, or an Earnings Release (ER) if it were just highlights. However, the depth of operational review and the focus on the full fiscal year strongly suggest a primary annual financial disclosure. In the context of the provided codes, the closest match for a comprehensive annual financial summary, even if preliminary or in a local format, is the Annual Report (10-K). If it were strictly a brief press release of results, ER would fit, but the length and detail lean towards a more comprehensive report summary. Given the Swedish context, this is the primary annual financial disclosure document. FY 2009
2010-02-17 Swedish
Interim / Quarterly Report 2009
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Year-end Report January-December 2009' for Orexo AB. It contains comprehensive financial data, including net revenues, loss after tax, loss per share, and cash equivalents for the full fiscal year and the fourth quarter. It also includes detailed management commentary, operational updates, and product portfolio status. As it covers a period shorter than a full fiscal year (the fourth quarter) and provides substantive financial analysis and results for the year-end, it is classified as an Interim/Quarterly Report. FY 2009
2010-02-17 English
Regulatory Filings 2010
Regulatory Filings Classification · 1% confidence The document is a short press release dated February 4, 2010, announcing that Orexo's partner has confirmed a 'Regulatory Filing' (New Drug Submission) for AbstralTM has been accepted for review by Health Canada. It is not a comprehensive financial report (like 10-K or IR), nor is it a transcript or a formal dividend notice. It is an announcement regarding a regulatory/legal step concerning a product. Given the options, this type of announcement about a regulatory submission acceptance fits best under 'Regulatory Filings' (RNS) as a general regulatory update, although it is related to legal/product development. Since it is a specific announcement about a regulatory action (submission acceptance), and not a general legal proceeding (LTR) or a financing event (CAP), RNS serves as the most appropriate general regulatory announcement category, especially considering its short length and nature as a press release update.
2010-02-04 English
Regulatory Filings 2010
Regulatory Filings Classification · 1% confidence The document is a press release dated February 4, 2010, announcing that a New Drug Application (NDA) for the product Abstral has been accepted for evaluation by Health Canada. It details regulatory progress, product information, and contact details. This type of announcement, which is a formal communication about a specific regulatory or business event (drug application acceptance), does not fit neatly into the core financial reporting categories (10-K, IR, ER, etc.). Since it is a formal, non-financial regulatory update concerning a specific legal/regulatory step (NDA acceptance), and it is not a general regulatory filing fallback (RNS) or a legal proceeding report (LTR), the most appropriate category for a specific, non-financial regulatory/business update that doesn't fit elsewhere is the general Regulatory Filings category (RNS), as it serves as a broad announcement mechanism for material, non-standardized news. Given the short length and nature as a press release announcing a regulatory event, RNS is the best fit among the provided options, acting as a catch-all for significant, non-standardized corporate news releases.
2010-02-04 Swedish
Regulatory Filings 2010
Regulatory Filings Classification · 1% confidence The document is titled "Pressmeddelande" (Press Release) and announces a specific business event: a distribution agreement between Orexo and its partner Kyowa Hakko Kirin regarding a drug (KW-2246) in Japan. It includes quotes from the CEO and contact information. Crucially, the final note states: "Informationen är sådan som Orexo AB (publ) ska offentliggöra enligt lagen om handel med finansiella instrument och/eller lagen om värdepappersmarknaden." This indicates a mandatory regulatory disclosure of material information. Since it is a press release announcing a significant business development (partnership/distribution agreement) rather than a specific financial report (like 10-K, IR, ER) or a shareholder vote result, it fits best under the general regulatory announcement category, which is RNS (Regulatory Filings), as it is a broad disclosure required by market regulations that doesn't fit the more specific categories like DIV, CAP, or M&A (TAR). Given the short length (3143 chars) and the nature of announcing a deal, RNS is the most appropriate fit among the options provided for a general regulatory announcement.
2010-02-02 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.